

NEEDLE-FREE DIABETES MANAGEMENT

Abstract

~~According to this article, Microneedles-microneedles~~ are used in automated diabetes therapy systems, ~~according to this article~~. By bridging diagnostics and therapeutics, advanced bioengineered systems could constitute a "smart" system for diabetes treatment. Oral, hypodermic, through the nose, and other modes of delivery all have limitations, such as pain and other side effects. Physical entities are transferred through the skin by most ~~Glucose~~ glucose monitoring devices and conservative insulin treatments. It is well known that automated diabetes treatment systems involve very multifaceted interdependencies between various entities; and, as such, require multidisciplinary research programs. ~~To In order to~~ develop an iterative, noninvasive bioengineered interface such as microneedles, we need a better ~~empathetic-understanding~~ of the human skin's molecular architecture and its functioning as a functional unit of the body. Specifically for auto-diabetes therapy, ~~the Microneedle-microneedle~~ interfaces system in this article is examined from the perspective of application-specific requirements.

Keywords: bio-microelectromechanical systems, diabetes therapy, microneedles.

INTRODUCTION

Diabetes Mellitus and its Treatment

~~Diabetes mellitus-Mellitus~~ is a chronic metabolic disorder associated with carbohydrate and protein metabolism. After a certain period ~~of time~~, it is often accompanied by specific microvascular, macrovascular, and neurologic complications. In the year 2014, it is estimated that around 422 million people globally had diabetes, compared to 108 million in 1980. It has also been observed that the number of diabetic patients among adults has increased by 4.7%–8.5% since 1980, which

is thought to have doubled ~~since~~ 1980. There is an increase in overweight and obese risk factors as well. [1,2]

Diabetes comes in two forms:

~~1st~~ First diabetes is typically managed using insulin, whereas ~~second~~ 2nd diabetes is usually managed using oral hypoglycemic agents. It is a metabolic disorder that is associated with a host of ~~Companion~~ companion problems and contributes to ~~Death~~ death before its time. Comorbidities such as heart attacks, strokes, ~~Failure~~ failure of the kidneys, amputations have been reported.; There have been reports of vision loss and nerve damage.[3]

Presently, there are several different types of insulin preparations available, each of which acts differently. In reality, manual insulin administration is an estimated therapy. The most common side effects include nausea and an upset stomach. As a result, the immune system becomes weak, leading to additional complications. Due to its breakdown by the gastrointestinal tract, insulin is incapable of passing through the gastrointestinal membrane. Insulin is incapable of passing through the gastrointestinal membrane due to its breakdown by the gastrointestinal tract. [1,3]

Different delivery mechanisms for insulin exist depending on how it is administered: ~~Whether~~ whether it is given by injection, injection under the skin, intraperitoneal injection, or nasal injection. Injection under the skin is the most common mechanism due to its precise dosage control. [4]

It is very tedious and difficult to produce insulin in natural form; additionally, the obtainable technique could not either reproduce or qualify the highest insulin levels, Because of limitations on oral Injecting insulin, discomfort, trauma, and low compliance with injectable forms of insulin, researchers have begun experimenting with the transdermal application of insulin. Therefore, this review describes the dDelivery of insulin via microneedles into the stratum corneum via the transdermal route. [5,6]

A Model for Drug Delivery

The main functions of the skin are to act as a physical barrier and as a receiver of peripheral stimuli. The skin is made up of three layers: the epidermis, dermis, and hypodermis.

Insulin is delivered intravenously through microneedles through the stratum corneum. The stacked dead cells are continuously replaced by new cells formed in the basal layer. Hair follicles, sweat glands, and blood vessels are found in the core dermis, which is connected to nerve endings by nerve ending connections. Adipose tissue is found in the hypodermis, which provides insulating characteristics ~~to~~for the body.[7,8]

The main function of the skin is to protect the body from harmful substances and microorganisms. In addition, Besides that, the stratum corneum in our skin is the best barrier against diffusion because it isn't very good at letting electricity move through it. Up to 90% of the time, transdermal drugs can get through the stratum corneum, which is the most important thing that stands in the way of diffusion. [9]~~the stratum corneum in our skin provides the greatest barrier against diffusion since it is a poor conductor of electricity. Transdermal drugs can diffuse up to 90% of the time through the stratum corneum, the most significant barrier to diffusion.~~ [10]

The Transdermal Drug Delivery System

Transdermal drug delivery through the skin provides a convenient method of deep penetration into the systemic circulation and is employed for controlled drug delivery. Drugs are transported into the skin layer so they can be administered ~~in a systemic manner~~systemically. [11] Using patches to deliver hydrophobic drugs is a unique and brilliant solution. This is overcome with micrometer-scale needles, which utilize a unique technological approach to enhance drug permeation across the skin, resulting in better insulin delivery compared to needles that require infection for delivery. Several issues with drug development have been solved using transdermal delivery in recent years. For instance, only a few transdermal drugs are currently available, despite their many benefits; in addition, many of them have limited permeability across the stratum corneum. Transdermal delivery of many drugs is said to be able to get around many of the things that make oral, injectable, or inhaled drugs less effective. Transdermal delivery of many drugs is reported to overcome many of the factors that limit orally delivered, injectable, or inhaled drugs. [12,13]

The use of ~~Skin-skin~~ patch systems for the effective delivery of drugs systemically has ~~a number of~~advantages, including cCompliance among patients improved, and eliminating Metabolism of first-pass hepatocytes ~~Oral-oral~~ drug delivery systems are more efficient than injectable drug delivery systems. [14,15] The use of this system prevents adverse reactions

caused by overdosing and is convenient, especially in terms of transdermal patches, which need to be applied only once a week, resulting in patient adherence to drug therapy. It can enhance the bioavailability and ~~are able to~~can deliver high concentrations of drugs to the site of action, thereby reducing ~~the~~systemic drug levels. Because transdermal delivery doesn't cause as much pain and inconvenience as intravenous injections, it's a good way to transport drugs or biological compounds.~~Because transdermal delivery reduces the pain and inconvenience associated with intravenous injections, it is an attractive method to transport drugs or biological compounds.~~ [16,17]

This had some limitations, such as local irritation, erythema, ~~or~~itching at the site of application, or swelling caused by other excipients, especially with patch formulations. The limited permeability of the skin can limit the number of drugs that can be delivered. ~~In order~~
~~to~~To overcome these limitations, numerous efforts have been made to develop conventional methods of delivering drugs. [18]

Transdermal drug delivery may have enabled a greater increase in lipophilic drug delivery in the transdermal system than oral and injectable delivery. In addition, ~~it~~ontophoresis may have helped to increase the amount of lipophilic delivery of the transdermal system. There is no physiochemical property of the drug; therefore, some physical or chemical enhancers are needed to improve the diffusion of the drug. Therefore, electroporation, sonophoresis, iontophoresis, and MN have all been developed. [19,20]

Microneedles: A New Approach

Nanoneedles are recently developed systems for the delivery of drugs that are similar or similar to traditional needles, except they are created on a ~~micron-micron~~-scale and can range from 1-100 microns in diameter and length.[21] Microneedles are needles arranged on a transdermal patch in a microneedle pattern; and are currently used to enhance the delivery of small and large molecules through transdermal delivery systems. Medical MN devices are used to treat the condition; tiny microchannels can be created ~~b~~By way of the stratum corneum. There are different brands and variants of these devices available. The University of Marburg, Germany, tried the MN method and found that both lipophilic and hydrophilic compounds get into the body more easily when they are given by MN.~~The University of Marburg, Germany, tested the MN approach and found that both lipophilic and hydrophilic compounds penetrate much better when administered by MN.~~ [22]

~~Since the MNs are arranged in arrays,~~ Drug delivery by transdermal means can be improved with this technology since they are designed to penetrate only the ~~Skin-skin~~ surface without going deep and stimulating the dermal nerves. Due to ~~the~~ short needle length of MN patches, the nerves ~~are not stimulated~~ in the stratum corneum ~~are not stimulated~~. [23]

Micron-sized pores in MNs facilitate the delivery of micromolecular-size drugs into ~~the~~ body. It has been suggested that large molecules might be coated on MNs, which may then be injected through the skin. ~~MN is a hollow state. A hollow MN,~~ Alternatively, ~~The the~~ drug is directly injected into the skin, whereas microneedles dissolve when you apply and release the ~~Sideside~~-effect-free ~~drug~~ ~~Currently~~ ~~drug currently~~, clinical trials are being conducted into the development of microneedles that deliver macromolecules like insulin, parathyroid hormone, and influenza vaccine. [24] As with conventional needles, the microneedles can be arranged into arrays at the microscale. Additionally, microneedles ~~s~~ can be made into patches that can be applied to the skin. Often, transdermal drug delivery fails to deliver ~~delivering~~ drugs to the skin at a therapeutic rate; this results in a statistically limited success rate. Therefore, ~~the~~ uses of microneedle patches ~~were was~~ found to be effective in increasing transdermal drug delivery as well as enhancing the skin's permeability. [25]

Solid microneedle

In passive diffusion, solid microneedles increase skin permeability by creating microchannels, and then they are applied with a patch that contains drugs. ~~In order to~~ To prevent the spread of pathogenic bacteria or toxic substances, ~~it is necessary for microchannels to promptly close once the needles have been removed.~~ ~~it is necessary for microchannels once the needles have been removed, close promptly.~~ [26,27] As mentioned in numerous published studies, solid MN arrays have been shown. For instance, insulin, calcium, naltrexone, or proteins can get through the skin better. [28]

Solid arrays of microneedles (MNs) coated with macromolecules are used to "coat and poke" ingredients onto the stratum corneum. Drug coating of the MN array can be accomplished in many ways. It has proven effective to deliver macromolecules such as nucleic acids, proteins, and vaccines through MN arrays that are coated with gelatin. Drug coating of the MN array can be accomplished in many ways. It has been shown that coated MN arrays are effective at delivering macromolecules like proteins, nucleic acids, and vaccines to the skin. ~~It might be possible to coat a MN with a powerful drug or vaccine, but it's not a good way to get a lot of active~~

~~molecules. It may be feasible to coat a MN to deliver potent drugs or vaccines, but it is not an effective way to transport large amounts of active molecules.~~ [29]

Hollow microneedle

The hollow MNs deliver drugs using a "poke-and-flow" approach. Like with hypodermic injections, the fluid drug can flow constantly into the skin as it flows through the holes in the hollow MNs. [30] A micropump, for example, can be used to precisely control the flow rate of the drug. As compared to hard microneedles, hollow microneedles are additionally probable to facilitate fFluid flow driven by force. As a result, drugs can be delivered faster. Further, hollow MNs can provide painless, continuous, and long-term drug delivery tTo meet the specific needs of each patient, with precise and tunable dosages. [31,32]

Dissolving microneedle

Microneedles that melt into the skin after insertion of the active substance ~~is~~ are dissolved or biodegraded into the matrix. For the manufacture of microneedles, micromolding techniques are used. The most commonly used substances are sugars, carbohydrates, and synthetic polymers to create these arrays, which can deliver insulin, high cCombining dissolving microneedle with iontophoresis improves the delivery of the drug to the skin, as it is combined with molecular-weight heparin, ovalbumin, vaccine antigens, and photosensitizers. [33]

Hydrogel-forming microneedle

Microneedles with hollow bores have a hollow bore located in their center. Drugs are defused by hydrogel-forming microneedle arrays by absorbing interstitial fluid via distended micro projections. They are created from artificial polymers. Micro and macromolecules can be distributed through microneedle hydrogels. [34]

~~The A microelectromechanical system is an integrated mechanical, sensor, actuator, and electronic device built using microfabrication. Skill-A skill like this will make it possible to integrate the complete system on a chip, allowing for better glucose control and management. This technology makes it possible to deliver drugs to the body without being invasive or hurting the body. Subcutaneous drug delivery with this technology provides an opportunity for noninvasive and pain-free delivery of drugs.~~ [35]

Autonomous Diabetes Management

Many of the problems that come with manually injecting insulin can be solved with an insulin treatment system that uses automatic glucose monitoring and changes the way insulin is injected.

~~Many of the issues associated with manual insulin injections can be addressed through an insulin treatment system that uses automatic glucose monitoring in addition to altering the injection technique.~~ [36] The following generic devices are important: An insulin delivery system that binds the glycemic level and insulin delivery gap using (a) glucose devices and (b) a response device. ~~An insulin delivery system that uses (a) glucose devices and (b) a response device to bond the glycemic level and insulin delivery gap.~~ An insulin therapy device's response mechanism is a key component. Glucose adsorption triggers insulin production, which is a very complex process. The program should be able to tailor glucose levels versus insulin delivery schemes that optimally match ~~will optimally~~ the patient's real metabolic activities should be matched. [37,38]

Researchers in diabetes research are increasingly using closed-loop systems utilizing microneedles due to ~~its~~ their high priority features. It is only possible to design MNs that are application-specific and algorithm-dependent. MN involves multiple parameters to consider and highly application-specific designs. [39]

Microneedle for Glucose Sensing

Many studies have shown that blood glucose levels differ from those measured by ISF. Both methods can be used to determine blood glucose levels. A period break of 0 to 45 minutes ~~estimates are is~~ usually made based on the observations rate at which glucose travels from the blood to the ISF. [40]

As soon as equilibrium is reached, blood and ISF levels correlate. The depth of penetration of the microneedle should be about 50-150 μ^* m for ISF to be extracted. Consequently, the application of shorter needles of the same diameter can withstand more pressure without fail ~~ureing~~ without fracture caused by buckling, and without buckling caused by buckling. ~~and buckling caused by buckling.~~ The reduction in height for a smaller needle diameter may prevent buckling. An array of MNs is used to detect changes in glycemic levels, and then inject insulin within 20 minutes. [41,42]

Microneedle for Insulin Delivery

Despite the great changes in noninvasive glucose monitoring, the devices still rely on inexact mathematical algorithms, causing many complications. On the other hand, traditional methods use hypodermic needles that are painful and traumatic to the tissues. [43]

It is considered difficult to deliver insulin transdermally because the particles ~~is~~ are very big. These problems can be solved with microneedles, as they are considered ~~Low~~ low-invasive tools for interacting with the skin. In the MN technology, miniature pores are created to allow insulin to penetrate ~~into~~ the stratum corneum, preventing it from passing through. ~~Stratum~~ The stratum corneum is then able to receive insulin. [44,45] An enzyme, glucose oxidase, has recently been used in MN along with insulin. Blood tests to detect hypoxia and releasing insulin inappropriately. Pumps deliver the fluid, which is controlled by a feedback system. Active pumping eliminates capillary force dependence. Consequently, ~~the~~ The role of material choice ~~Based~~ based on the degree of hydrophilicity, hydrophilic properties play a key role. Polymers and metals have all been used for microneedles that deliver insulin painlessly into the stratum corneum. For a painless delivery of insulin ~~Insulin delivery~~ to the stratum corneum, the ~~Microneedle~~ microneedle tip's lumen diameter should be between 10 and 100 microns. [47- 49]

By delivering insulin through MN technology, glucose levels in animals have been reduced substantially. A 47% to 80% reduction in glycemic levels was observed in studies when 0.05 to 0.5 units of insulin were delivered. [50] When MN is inserted into the stratum corneum to insert insulin, ~~it is likely that~~ likely, MN can occasionally become clogged or trapped. ~~In order, to~~ To deliver insulin through MNs painlessly and for a prolonged period ~~of time~~, ~~approximately~~ It is possible to arrange and place 100 microneedles 200m apart in the array. By doing this, in a short-half-life, it is possible to deliver insulin more frequently from the stratum corneum into the stratum membranous. [51,52]

Challenges

Translating MNs from lab benches into feasible products in relevant markets will be a challenging task ~~towards~~ in the future. In order to use this advanced technology, every step needs to be done well; the following questions and challenges need to be addressed as soon as possible. All these, and other challenges ~~pertaining to~~ to this field, are discussed herein, as are active strategies to resolve these issues, which could play a crucial role in its future. [54,55]

~~Failure of MNs could cause the wrong dose to be given because they must be strong and reliable for repeated penetration and long-term use. Failure of MNs could lead to incorrect dosage administration because they must be strong and reliable for repeated penetration and for extended use.~~ [56] It is also important to consider the level of biocompatibility because of its continuous use requirements. Even though silicon is more versatile than some other metals for microneedle construction, its biocompatibility varies based on the application. Silicon is a versatile material for microneedle fabrication, but it is the grade of ~~Application~~application-dependent biocompatibility. [57,58] The use of recyclable polymer-based microneedles s needs to be explored. Certain investigators ~~are of the opinion~~believe that the continuous distribution of insulin via a supplementary pump system requires a constant source of insulin, whereas a microneedle maintains the same level of insulin using less insulin. Traditionally, an ~~Infrequently~~infrequently occurring slow-acting injection of ~~A~~a longer time is needed for insulin to take effect in patients with diabetes. Long-term controlled injections could maintain insulin concentration by delivering short half-insulin more frequently. [59,60]

Conclusion

~~It is highly likely that microneedle-based drugs will~~Microneedle-based drugs will likely be marketed soon. Researchers are conducting extensive research to deliver therapeutics efficiently via microneedles, ~~it~~It is urgent for ~~m~~Methods for delivering drugs transdermally to be developed for ~~Matrices that are hydrophilic~~hydrophilic Matrices, macromolecules, proteins, and conventional medicines for use in new therapeutic indications. Transdermal delivery of microneedles s either as patches or arrays, s appears to be a rational method to better manage diabetes through effective insulin delivery. Compared to other injectable methods, the microneedle approach is painless, efficacious, safe, and effective. Because they don't hurt, they could also be a major tool for controlled drug release in the future.~~They may also be suitable to be a significant device for controlled drug release in the future, because they are painless.~~ An MN interface would provide a noninvasive, bioengineered way to understand the skin; this approach can be implemented in ~~a number of~~several ways.

A painless insertion may reduce discomfort and the likelihood of noncompliance among patients, ~~to reduce~~reducing the risk of human error. Additionally, microneedling ~~has increased~~attracted much attention because of its ~~Concept~~concept of minimal training that is particularly useful for children with diabetes. Microneedles are therefore a possible option for improving ~~Control~~control of blood sugar, allowing for more efficient and contented diabetes organization, and reducing the risk of long ~~time~~term complications associated with diabetes. Thus, it shows that when it comes to better patient compliance and management, transdermal delivery of MN-based technology is a lot better than other injectables. ~~Thus, it demonstrates that transdermal delivery of MN-based technology is considerably superior and effective than other injectables when it comes to better patient compliance and management.~~

References

1. Khanna P, Strom JA, Malone JJ, Bhansali S. Microneedle-based automated therapy for diabetes mellitus. *J Diabetes Sci Technol*. 2008;2:1122–9. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
2. Hultström M, Roxhed N, Nordquist L. Intradermal insulin delivery: A promising future for diabetes management. *J Diabetes Sci Technol*. 2014;8:453–7. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
3. Akhtar N. Microneedles: An innovative approach to transdermal delivery – A review. *Int J Pharm Pharm Sci*. 2014;6:18–25. [[Google Scholar](#)]
4. Yu J, Zhang Y, Ye Y, DiSanto R, Sun W, Ranson D, et al. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. *PNAS*. 2015;112:8260–5. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
5. Microneedles: an approach in transdermal drug delivery: a Review Devender Sharma Hi – Tech college of pharmacy, Chandrapur, Maharashtra, India.
6. Hovorka R. Continuous glucose monitoring and closed-loop systems. *Diabet Med*. 2006;23:1–12. [[PubMed](#)] [[Google Scholar](#)]
7. Takahashi D, Xiao Y, Hu F. A survey of insulin-dependent diabetes-part II: Control methods. *Int J Telemed Appl*. 2008;739385:1–14. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

8. Spencer WJ. A reviewed of programmed insulin delivery systems. *IEEE Trans Biomed Eng.* 1981;28:237–51. [[PubMed](#)] [[Google Scholar](#)]
9. Kulcu E, Tamada JA, Reach G, Potts RO, Lesho MJ. Physiological differences between interstitial glucose and blood glucose measured in human subjects. *Diabetes Care.* 2003;26:2405–9. [[PubMed](#)] [[Google Scholar](#)]
10. Kaushik S, Hord AH, Denson DD, McAllister DV, Smitra S, Allen MG, et al. Lack of pain associated with microfabricated microneedles. *Anesth Analg.* 2001;92:502–4. [[PubMed](#)] [[Google Scholar](#)]
11. Friedl KE. Analysis: Optimizing microneedles for epidermal access. *Diabetes Technol Ther.* 2005;7:546–8. [[PubMed](#)] [[Google Scholar](#)]
12. Microneedle – Future prospect for efficient drug delivery in diabetes management
[Baishali A. Jana](#) and [Ashish D. Wadhwani](#)
13. Wang PM, Cornwell M, Prausnitz MR. Minimally invasive extraction of dermal interstitial fluid for glucose monitoring using microneedles. *Diabetes Technol Ther.* 2005;7:131–41. [[PubMed](#)] [[Google Scholar](#)]
14. Tsuchiya K, Nakanishi N, Uetsuji Y, Nakamachi E. Development of blood extraction system for health monitoring system. *Biomed Microdevices.* 2005;7:347–53. [[PubMed](#)] [[Google Scholar](#)]
15. Gattiker GE, Kaler KV, Mintchev MP. Electronic mosquito: Designing a semi-invasive microsystem for blood sampling, analysis and drug delivery applications. *Microsyst Technol.* 2005;12:44–51. [[Google Scholar](#)]
16. Caduff A, Hirt E, Feldman Y, Ali Z, Heinemann L. First human experiments with a novel non-invasive, non-optical continuous glucose monitoring system. *Biosens Bioelectron.* 2003;19:209–17. [[PubMed](#)] [[Google Scholar](#)]
17. Henry S, McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles: A novel approach to transdermal drug delivery. *J Pharm Sci.* 1998;87:922–5. [[PubMed](#)] [[Google Scholar](#)]
18. Park JH, Allen MG, Prausnitz MR. Polymer microneedles for controlled-release drug delivery. *Pharm Res.* 2006;23:1008–19. [[PubMed](#)] [[Google Scholar](#)]

19. Park JH, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: Fabrication, mechanics and transdermal drug delivery. *J Control Release*. 2005;104:51–66. [[PubMed](#)] [[Google Scholar](#)]
20. Davis SP, Martanto W, Allen MG, Prausnitz MR. Hollow metal microneedles for insulin delivery to diabetic rats. *IEEE Trans Biomed Eng*. 2005;52:909–15. [[PubMed](#)] [[Google Scholar](#)]
21. Chandrasekaran S, Frazier AB. Characterization of surface micromachined metallic microneedles. *J Microelectromech Syst*. 2003;12:289–95. [[Google Scholar](#)]
22. Rodriguez A, Molinero D, Valera E, Trifonov T, Marsal LF, Pallares J, et al. Fabrication of silicon oxide microneedles from macroporous silicon. *Sens Actuators B Chem*. 2005;109:135–40. [[Google Scholar](#)]
23. Rajaraman S, Henderson HT. A unique fabrication approach for microneedles using coherent porous silicon technology. *Sens Actuat B Chem*. 2005;105:443–8. [[Google Scholar](#)]
24. Wilke N, Hibert C, O'Brien J, Morrissey A. Silicon microneedle electrode array with temperature monitoring for electroporation. *Sens Actuators A Phys*. 2005;123-124:319–25. [[Google Scholar](#)]
25. Martanto W, Davis SP, Holiday NR, Wang J, Gill HS, Prausnitz MR, et al. Transdermal delivery of insulin using microneedles in vivo. *Pharm Res*. 2004;21:947–52. [[PubMed](#)] [[Google Scholar](#)]
26. Perennes F, Marmioli B, Matteucci M, Tormen M, Vaccari L, Fabrizio ED. Sharp beveled tip hollow microneedle arrays fabricated by LIGA and 3D soft lithography with polyvinyl alcohol. *J Micromech Microeng*. 2006;16:473–9. [[Google Scholar](#)]
27. Stoeber B, Liepmann D. Arrays of hollow out-of-plane microneedles for drug delivery. *J Microelectromech Syst*. 2005;14:472–9. [[Google Scholar](#)]
28. Davis SP, Landis BJ, Adams ZH, Allen MG, Prausnitz MR. Insertion of microneedles into skin: Measurement and prediction of insertion force and needle fracture force. *J Biomech*. 2004;37:1155–63. [[PubMed](#)] [[Google Scholar](#)]

29. Takahashi D, Xiao Y, Hu F, Lewis M. A survey of insulin-dependent diabetes-part I: Therapies and devices. *Int J Telemed Appl*. 2008;639019:1–15. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
30. Sheer A, Chauhan M. Ethosomes as vesicular carrier for enhanced transdermal delivery of ketoconazole formulation and evaluation. *IJPI's J Pharm Cosmetol* 2011; 1(3): 1-14.
31. Alvarez-Figueroa M, Delgado-Charro M. Passive and iontophoretic transdermal penetration of methotrexate. *Int J Pharm* 2001; 212: 101-107.
32. Nolan LMA, Corish J, Corrigan OI, Fitzpatrick D. Iontophoretic and chemical enhancement of drug delivery: Part-I: Across Artificial Membranes. *Int J Pharm* 2003; 257: 41-55.
33. Bendas ER, Tadros MI. Enhanced transdermal delivery of salbutamol sulphate via ethosomes. *AAPS PharmSciTech* 2007; 8: 1-15.
34. Saroha K, Nanda S, Rani S. Chemical penetration enhances: a novel approach in transdermal drug delivery system. *Int J Curr Pharm Res* 2011; 3(4): 5-9.
35. Kumar AV, Kulkarni PR, Raut RA. Microneedles: promising technique for transdermal drug delivery. *Int J Pharm Bio Sci* 2011; 2(1): 684-708.
36. Tabassum N, Sofi A, Khuroo T. Microneedle technology: a new drug delivery system. *Int J Res Pharm Biomed Sci* 2011; 2(1): 59-62.
37. Srinivas P, Shanthi CL, Sadanandam MS. Microneedles patches in drug delivery: a review. *Int J Pharm Tech* 2010; 2(3): 329-344.
38. Vandervoort J, Ludig A. Microneedles for transdermal drug delivery: a minireview. *Front Biosci* 2008; 1(13):1711-1715.
39. Yadav JD. Microneedles: promising technique for transdermal drug delivery. *Int J Pharm BioSci* 2011; 2(1):684-708.
40. Paik SJ, Lim JM, Jung I, Park Y, Byun S, Chung S. A novel microneedle array integrated with a PDMS biochip for micro fluid system. *Transducers Solid-State Sensors Actuators Microsys* 2003; 2: 1446-1449.

41. Uddin MJ, Scoutaris N, Klepetsanis P, Chowdhry B, Prausnitz MR, Douroumis D. Inkjet printing of transdermal microneedles for the delivery of anticancer agents. *Int J Pharm.* 2015;494(2):593-602.
42. Ross S. Inkjet printing of insulin microneedles for transdermal delivery. *Drug Deliv Translation Res.* 2015;5(4):451-461.
43. Economidou SN, Lamprou DA, Douroumis D. 3D printing applications for transdermal drug delivery. *Int J Pharm.* 2018;544(2): 415-424.
44. O'mahony C, Leonie H, Tobias K, et al. Accuracy and feasibility of piezoelectric inkjet coating technology for applications in microneedle-based transdermal delivery. *Microelectronic Eng.* 2017;172:19-25. doi:org/10.1016/j.mee.2017.02.018.
45. Kim YC, Fu-Shi Q, Richard W, et al. Formulation of microneedles coated with influenza virus-like particle vaccine. *AAPS Pharm Sci Technol.* 2010;11(3):1193-1201.
46. Zeng Q, Gammon JM, Tostanoski LH, Chiu YC, Jewell CM. In vivo expansion of melanoma-specific T cells using microneedle arrays coated with immune-polyelectrolyte multilayers. *ACS Biomater Sci Eng.* 2017;3(2):195-205.
47. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. *J Control Release.* 2010;142(2):187-195.
48. Han M, Dae KK, Seong HK, et al. Improvement in antigen delivery using fabrication of a grooves-embedded microneedle array. *Sens Actuat Chem.* 2009;137(1):274-280.
49. Shen QI, Ying C, Xiang C, Xiaolin Z. The fabrication and property of a novel coated out-of-plane microneedle arrays. *Microsys Technol.* 2015;22(1):143-149.
50. Gill HS, Prausnitz MR. Pocketed microneedles for drug delivery to the skin. *J Phys Chem Solids.* 2008;69(5-6):1537-1541.
51. Jung D, Rejinold NS, Kwak JE, Park SH, Kim YC. Nanopatterning of a stainless steel microneedle surface to improve the dip-coating efficiency of a DNA vaccine and its immune response. *Colloids Surf B Biointerf.* 2017;159:54-61.

52. Ullah A, Kim C M, Kim GM. Porous polymer coatings on metal microneedles for enhanced drug delivery. *R Soc Open Sci.* 2018; 5(4):171609.
53. Hao Y, Li W, Zhou X, Yang F, Qian Z. Microneedles-based transdermal drug delivery systems: a review. *J Biomed Nanotechnol.* 2017;13(12):1581-1597.
54. Sullivan SP, Koutsouanos DG, Del Pilar Martin M, et al. Dissolving polymer microneedle patches for influenza vaccination. *Nat Med.* 2010;16(8):915-920
55. Li QY, Jia Nan Z, Bo Zhi C, Qi Lei W, Xin Dong G. A solid polymer microneedle patch pretreatment enhances the permeation of drug molecules into the skin. *RSC Adv.* 2017;7(25): 15408-15415.
56. Vinayakumar KB, Prachit GK, Nayak MM, et al. A hollow stainless steel microneedle array to deliver insulin to a diabetic rat. *J Micromech Microeng.* 2016;26(6):065013.
57. Pamornpathomkul B, Wongkajornsilp A, Laiwattanapaisa W, Rojanarata T, Opanasopit P, Ngawhirunpat T. A combined approach of hollow microneedles and nanocarriers for skin immunization with plasmid DNA encoding ovalbumin. *Int J Nanomed.* 2017;12:885-898.
58. Li CG, Lee CY, Lee K, Jung H. An optimized hollow microneedle for minimally invasive blood extraction. *Biomed Microdevices.* 2012;15(1):17-25.
59. Rodgers AM, Courtenay AJ, Donnelly RF. Dissolving microneedles for intradermal vaccination: manufacture, formulation, and stakeholder considerations. *Expert Opin Drug Deliv.* 2018; 15(11):1039-1043.
60. Zhu J, Shen QI, Ying C, et al. Characterization of out-of-plane cone metal microneedles and the function of transdermal delivery. *Microsyst Technol.* 2012;19(4):617-621.